Different roles of radical scavengers - Ascorbate and urate in the cerebrospinal fluid of amyotrophic lateral sclerosis patients

Redox Report

Volumn 15, Issue 2, 2010, Pages 81-86

  Spasojević, Ivan ^a   Stević, Zorica ^b   Nikolić Kokić, Aleksandra ^c   Jones, David R ^d   Blagojević, Duško ^c   Spasić, Mihajlo B ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Ascorbate; Epr; Iron; Urate

Indexed keywords

ASCORBIC ACID; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; SCAVENGER; URATE; URIC ACID;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BIOCATALYSIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; EX VIVO STUDY; FEMALE; HUMAN; IRON KINETICS; MALE; NERVE DEGENERATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; ASCORBIC ACID; CEREBROSPINAL FLUID; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICAL SCAVENGERS; HUMANS; URIC ACID;

EID: 77952467640     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/174329210X12650506623320     Document Type: Article

References (44)

1. Strong M, Rosenfield J. Amyotrophic lateral sclerosis. A review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:136-143. (Pubitemid 37184881)
2. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005;5:77-87.
3. Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000;180:7-14.
4. Shaw PJ, Ince PG. Glutamate excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997;244: S3-S14.
5. Bolanos JP, Moro MA, Lizasoain I et al. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications. Adv Drug Deliv Rev 2009;61:1299-1315.
6. Tohgi H, Abe T, Yamazaki K et al. Remarkable increase in cerebrospinal fluid 3-nytrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1999;46:129-131.
7. Tohgi H, Abe T, Yamazaki K et al. Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 1999;260:204-206.
8. Okado-Matsumoto A, Fridovich I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc Natl Acad Sci USA 2002;99:9010-9014.
9. Ferrante RJ, Browne SE, Shinobu LA et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-2074.
10. Smith RG, Henry YK, Mattson MP et al. Presence of 4- hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998;44:696-699.
11. Shaw PJ, Strong M. (eds) Motor Neuron Disorders. New York: Butterworth Heinemann, 2003;285-313.
12. Ilieva EV, Ayala V, Jove M et al. Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain 2007;130:3111-3123.
13. Nakagomi S, Barsoum MJ, Bossy-Wetzel E et al. A Golgi fragmentation pathway in neurodegeneration. Neurobiol Dis 2008;29:221-231.
14. Valko M, Morris H, Cronin M T D. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12:1161-1208.
15. Oba H, Araki T, Ohtomo K et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993;189:843-846.
16. Cheung G, Gawal MJ, Cooper PW et al. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology 1995;194:263-270.
17. Bowen BC, Pattany PM, Bradley WG et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. Am J Neuroradiol 2000;21:647-658.
18. Hecht MJ, Fellner F, Fellner C et al. Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: a follow-up examination including FLAIR images. J Neurol Sci 2002;199:59-65.
19. Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Neurotoxicology 1993;14:445-450.
20. Leveugle B, Spik G, Perl DP et al. The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 1994;650:20-31.
21. Nikolic Kokic A, Stevic Z, Stojanovic S et al. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 2005;10:265-270.
22. Boll MC, Alcaraz-Zubeldia M, Montes S et al. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NOx content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008;33:1717-1723.
23. Liu D, Wen J, Liu J et al. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 1999;13:2318-2328.
24. Lyrer P, Landolt H, Kabiersch A et al. Levels of low molecular weight scavengers in rat brain during focal ischemia. Brain Res 1991;567:317-320.
25. Tayag EC, Nair SN, Wahhab S et al. Cerebral uric acid increases following experimental traumatic brain injury in rat. Brain Res 1996;733:287-291.
26. Langemann H, Feurerstein T, Mendelowitsch A et al. Microdialytical monitoring of uric and ascorbic acids in the brains of patients after severe brain injury and during neurovascular surgery. J Neurol Neurosurg Psychiatry 2001;71:169-174.
27. Stover JF, Lowittzsch K, Kempski OS. Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamatemediated excitotoxicity in different neurological diseases. Neurosci Lett 1997;238:25-28.
28. Brooks, BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:94-107.
29. Jackson SK, Liu KJ, Liu M et al. Detection and removal of contaminating hydroxylamines from the spin trap DEPMPO, and reevaluation of its use to indicate nitrone radical cation formation and S (N) 1 reactions. Free Radic Biol Med 2002;32:228-232.
30. Mojovic M, Bacic G, Vucinic Z et al. Oxygen radicals produced by plant plasma membranes: an EPR spin-trap study. J Exp Bot 2004;55:2523-2531.
31. Meret, S, Henkin, RI. Simultaneous direct estimation by atomic absorption spectrophotometry of copper and zinc in serum, urine, and cerebrospinal fluid. Clin Chem 1971;17:369-374.
32. Okamura M. An improved method for determination of L-ascorbic acid and L-dehydroascorbic acid in blood plasma. Clin Chim Acta 1980;103:259-268.
33. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006;1762:1051-1067.
34. Buettner G, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combination to avoid. Radiat Res 1996;145:532-541.
35. Halliwell B. Vitamin C: poison, prophylactic or panacea? Trends Biochem Sci 1999;24:255-259.
36. Halliwell B, Gutteridge J M C. Free Radicals in Biology and Medicine, 4th edn. Oxford: Oxford University Press, 2007.
37. Chen Q, Espey GM, Krishna MC et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-13609.
38. Spasojevic I, Mojovic M, Stevic Z et al. Bioavailability and catalytic properties of copper and iron for Fenton chemistry in human cerebrospinal fluid. Redox Rep 2009;15:29-35.
39. Castro MA, Beltrán FA, Brauchi S, Concha II. A metabolic switch in brain: glucose and lactate metabolism modulation by ascorbic acid. J Neurochem 2009;110:423-440.
40. Harrison FE, May JM. Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2. Free Radic Biol Med 2009;46:719-730.
41. Hooper DC, Scott GS, Zborek A et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 2000;14:691-698.
42. Whiteman M, Ketsawatsakul U, Halliwell B. A reassessment of the peroxynitrite scavenging activity of uric acid. Ann NY Acad Sci 2002;962:242-259.
43. O'Neill RD, Lowry JP. On the significance of brain extracellular uric acid detected with in-vivo monitoring techniques: a review. Behav Brain Res 1995;71:33-49.
44. Dujmovic I, Pekmezovic T, Obrenovic R et al. Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. Clin Chem Lab Med 2009;47:848-853.